Abstract 883P
Background
Mandibular bone resection is indicated in case of bone invasion or close contact with the tumor. The microvascular bone free flap (MBFP) is the reconstruction of choice. Despite a higher risk of complications, it allows oral rehabilitation. However, many patients do not benefit from it. We sought to assess the rate of non-rehabilitated patients and the reasons why.
Methods
This multicenter study was carried out in 6 centers in France. Patients were included if treated between January 2017 and January 2022 for head and neck carcinoma with MBFP. Patients who had relapsed or died were excluded. Included patients completed a telephone questionnaire.
Results
Of the 175 identified patients, 104 patients were finally included. Median follow-up since initial surgery was 26 months (min 18-max 60 months). MBFP consisted of a fibular free flap in 83% of cases, a scapular free flap in 16% of cases and an iliac crest free flap in 1% of cases. 61 patients (59%) had no oral rehabilitation. 17% of these patients had never been informed of the possibilities of oral rehabilitation, and 20% of these patients had never met any oral rehabilitation specialist. 22% of patients had an unsuccessful attempt at oral rehabilitation (removable prosthesis or implant-supported prosthesis). Of the 43 rehabilitated patients, 81% had a removable prosthesis and 19% an implant-supported prosthesis. Neither the number of osteotomies, nor the complexity of the reconstruction, nor the pre- or post-operative history of radiotherapy, nor the use of cutting guides were statistically associated with oral rehabilitation in this series. Only the presence of an oral rehabilitation specialist in the center had a significant influence on the rehabilitation rate (p=0.004), irrespective of the surgeon's specialty.
Conclusions
This is the first multicenter study to evaluate the rate of oral rehabilitation after free bone flap reconstruction for malignancy. Only 41% of patients benefited from rehabilitation. Regardless of the complexity of the reconstruction, the only factor influencing oral rehabilitation was the presence of an oral rehabilitation specialist in the center.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
879P - VERSATILE-002: Survival with first-line treatment with PDS0101 therapeutic vaccine and pembrolizumab in HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
Presenter: Jared Weiss
Session: Poster session 02
880P - Paclitaxel plus cetuximab for the treatment of recurrent and/or metastatic head and neck cancer after first-line checkpoint inhibitor failure: Primary analysis from the pace ace trial
Presenter: Thorsten Fuereder
Session: Poster session 02
881P - Cetuximab with dalpicilib in patients with HPV-negative, anti-PD-1 resistant R/M HNSCC
Presenter: Ju Houyu
Session: Poster session 02
882P - Quitting smoking after diagnosis of head and neck cancer is associated with reduced risk of mortality: A multicentric prospective cohort study
Presenter: Mahdi Sheikh
Session: Poster session 02
884P - Real-world treatment patterns and survival outcomes associated with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): A German claims data analysis
Presenter: Thomas Kuhnt
Session: Poster session 02
885P - Different patterns of treatment failure between p16+ and p16- patients affected by oropharyngeal carcinoma (OPC) undergoing (chemo)radiation
Presenter: Riccardo Gili
Session: Poster session 02
887P - Treatment of elderly patients with locally advanced laryngeal carcinoma with dose-intense chemotherapy followed by radio-chemotherapy: Evading surgical intervention
Presenter: Maher Salamoon
Session: Poster session 02
888P - Comparing paclitaxel plus cisplatin versus cisplatin in concurrent chemoradiotherapy for stage IV locoregionally advanced nasopharyngeal carcinoma: A phase II randomized trial
Presenter: Ling Guo
Session: Poster session 02